An ongoing dialogue on HIV/AIDS, infectious diseases,
November 30th, 2009
WHO HIV Treatment Guidelines Updated
This just in:
WHO is now recommending that ART be initiated at a higher CD4 threshold of 350 cells/mm3 for all HIV-positive patients, including pregnant women, regardless of symptoms.
Which makes eminent sense, of course. Because if starting HIV therapy might prolong survival in developed countries, why shouldn’t it do the same in the developing world?
In fact, when you consider the higher incidence of TB and invasive bacterial infections in such settings, it could easily be argued — and has been argued — that starting early would net greater survival gains in resource-poor settings than it would here.
Plus, there’s the CIPRAHT001 Study, which proves it.
But there’s more — the new WHO guidelines also urge that countries “phase out” the use of stavudine in favor of less-toxic NRTIs, and that women continue breastfeeding so long as they are also on ART.
Good news all around.
Categories: Health Care, HIV, Patient Care, Policy
Tags: AIDS, antiretroviral therapy, antiretrovirals, ART, guidelines, HIV, hiv treatment, Infectious Diseases, WHO
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
2 Responses to “WHO HIV Treatment Guidelines Updated”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
- When AI Gets the Medical Advice Wrong — and Right
- Rabies Is Terrifying — and the Challenge of Managing a Low Risk of a Dreadful Disease
- Influenza — So Familiar, Still So Mysterious
- Florida Moves to Cut AIDS Drug Assistance Program — and Drops the Most Prescribed HIV Regimen in the Country
- How the Z-Pak Took Over Outpatient Medicine
-
From the Blog — Most Recent Articles
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
- Florida Moves to Cut AIDS Drug Assistance Program — and Drops the Most Prescribed HIV Regimen in the Country January 27, 2026
- Rabies Is Terrifying — and the Challenge of Managing a Low Risk of a Dreadful Disease January 21, 2026
- Influenza — So Familiar, Still So Mysterious January 14, 2026
- How the Z-Pak Took Over Outpatient Medicine, Part 2: The Reckoning January 6, 2026
FROM NEJM — Recent Infectious Disease Articles- Pulmonary Mucormycosis February 12, 2026A 49-year-old man with acute myeloid leukemia was evaluated for prolonged neutropenic fever. On examination, there were crackles at the lung bases. CT of the chest revealed a reversed halo sign.
- Mucormycosis February 12, 2026Mucormycosis is a rapidly progressive, invasive fungal infection that causes severe disease. The latest epidemiologic data, risk factors, diagnostic strategies, and treatment approaches are reviewed.
- A Pediatrician’s Dilemma — Pushing Back against CDC Guidance in the Exam Room February 12, 2026When a mother cites the CDC as her source of dangerous misinformation about vaccines, her child’s pediatrician struggles: how hard can a doctor push back without destroying the trust built over a lifetime?
- Adenoviral Inciting Antigen and Somatic Hypermutation in VITT February 12, 2026VITT is caused by a somatic hypermutation of an anti–adenovirus pVII antibody that generates more avid binding of platelet factor 4 than of adenovirus pVII, its original target, which results in platelet activation.
- Dengue Suppression by Male Wolbachia-Infected Mosquitoes February 11, 2026In this report from Singapore, the release of wolbachia-infected, irradiated male Aedes aegypti mosquitoes resulted in a reduction in the vector population and in the risk of dengue infection.
- Pulmonary Mucormycosis February 12, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

Should the guidelines have suggested initiation at < 500 as is expected in the next iteration of US centered guidelines? Although ARVs are limited in many parts of the world should an individual patient be witheld therapy when there is an accumulation of data suggesting 500 (or higher) may be the tipping point? A conundrum in areas where supplies of ARVs are limited perhaps.
CM,
I guess one way of looking at “start at CD4 350” is “start at CD4 > 350.” I realize it’s not exactly the same thing, but since you can’t predict when or if the CD4 will drop, as a pt approaches this threshold (i.e., between 350 and 500), it’s time to get ready to start.
As you know, DHHS guidelines just out as well.
Paul